BECTON, DICKINSON AND COMPANY Becton, Dickinson and Company Share Price
Equities
BDX
US0758871091
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 236.3 USD | -0.14% |
|
+0.27% | -3.09% |
| Sales 2024 * | 20.23B 1,593B | Sales 2025 * | 21.42B 1,686B | Capitalization | 68.29B 5,376B |
|---|---|---|---|---|---|
| Net income 2024 * | 2.12B 167B | Net income 2025 * | 2.48B 195B | EV / Sales 2024 * | 4.03 x |
| Net Debt 2024 * | 13.21B 1,040B | Net Debt 2025 * | 10.71B 843B | EV / Sales 2025 * | 3.69 x |
| P/E ratio 2024 * |
32.4
x | P/E ratio 2025 * |
29.4
x | Employees | 73,000 |
| Yield 2024 * |
1.59% | Yield 2025 * |
1.63% | Free-Float | 77.74% |
More Fundamentals
* Assessed data
More news
Latest transcript on Becton, Dickinson and Company
More recommendations
More press releases
| 1 day | -0.14% | ||
| 1 week | +0.27% | ||
| Current month | +0.72% | ||
| 1 month | +0.93% | ||
| 3 months | -1.85% | ||
| 6 months | +1.30% | ||
| Current year | -3.09% |
1 week
234.37
238.95
1 month
230.00243.28
Current year
229.40249.89
1 year
229.40287.32
3 years
215.90287.32
5 years
197.75287.32
10 years
112.15287.32
| Managers | Title | Age | Since |
|---|---|---|---|
Thomas Polen
CEO | Chief Executive Officer | 50 | 31/12/08 |
| Director of Finance/CFO | 52 | 05/09/21 | |
| Chief Tech/Sci/R&D Officer | 48 | 31/12/18 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Bertram Scott
BRD | Director/Board Member | 73 | 23/09/02 |
Catherine Burzik
BRD | Director/Board Member | 73 | 28/01/13 |
| Director/Board Member | 69 | 25/07/10 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 15.40% | 254 M€ | +10.97% | - | |
| 2.47% | 6 M€ | +16.84% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 17/05/24 | 236.3 | -0.14% | 1,785,047 |
| 16/05/24 | 236.6 | -0.28% | 1,291,452 |
| 15/05/24 | 237.3 | +0.97% | 1,168,003 |
| 14/05/24 | 235 | -0.82% | 1,049,467 |
| 13/05/24 | 237 | +0.54% | 1,073,151 |
Delayed Quote Nyse, May 17, 2024 at 09:00 pm
More quotes
Becton, Dickinson and Company specializes in the development, manufacturing and marketing of medical and diagnostic equipment and materials. Net sales break down by family of products as follows:
- medical equipment (73.5%): surgical instruments, urological care products, pharmaceutical systems, etc.;
- diagnostic materials (18.7%): automated systems for blood testing, mycobacteria detection, and molecular biology, medical biology devices, etc.;
- clinical research and development tools (7.8%): tools for discovering drugs and vaccines, studying genes, culturing cells, and manipulating liquids, instruments for sorting and analyzing cells, monoclonal antibodies, etc.
Net sales are distributed geographically as follows: the United States (57.4%), Europe/Middle East/Africa (21.9%), Asia (15%) and other (5.7%).
Calendar
09/06/2024
- Ex-dividend day
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A
Sell
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
236.3
USD
Average target price
278.8
USD
Spread / Average Target
+17.99%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -3.09% | 68.29B | |
| -5.43% | 181B | |
| +4.30% | 114B | |
| +5.86% | 52.24B | |
| +8.15% | 44.3B | |
| +6.64% | 42.73B | |
| +25.54% | 32.52B | |
| +20.10% | 26.02B | |
| +1.00% | 25.91B | |
| -1.25% | 24.72B |
- Stock Market
- Equities
- BDX Stock
